Literature DB >> 32431257

A case series and literature review on patients with rhinological complications secondary to the use of cocaine and levamisole.

R J Green1, Q Gardiner1, K Vinod2, R Oparka3, P D Ross1.   

Abstract

BACKGROUND: Levamisole is an increasingly common cutting agent used with cocaine. Both cocaine and levamisole can have local and systemic effects on patients.
METHODS: A retrospective case series was conducted of patients with a cocaine-induced midline destructive lesion or levamisole-induced vasculitis, who presented to a Dundee hospital or the practice of a single surgeon in Paisley, from April 2016 to April 2019. A literature review on the topic was also carried out.
RESULTS: Nine patients from the two centres were identified. One patient appeared to have levamisole-induced vasculitis, with raised proteinase 3, perinuclear antineutrophil cytoplasmic antibodies positivity and arthralgia which improved on systemic steroids. The other eight patients had features of a cocaine-induced midline destructive lesion.
CONCLUSION: As the use of cocaine increases, ENT surgeons will see more of the complications associated with it. This paper highlights some of the diagnostic issues and proposes a management strategy as a guide to this complex patient group. Often, multidisciplinary management is needed.

Entities:  

Keywords:  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cocaine; Deformities; Nasal Obstruction; Nose

Mesh:

Substances:

Year:  2020        PMID: 32431257     DOI: 10.1017/S0022215120000894

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  1 in total

Review 1.  Distribution of cocaine-induced midline destructive lesions: systematic review and classification.

Authors:  Letizia Nitro; Carlotta Pipolo; Gian Luca Fadda; Giovanni Felisati; Alberto Maria Saibene; Fabiana Allevi; Mario Borgione; Giovanni Cavallo
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-02-09       Impact factor: 3.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.